Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M T Lotze

Showing results (221-230 of 242) with videos related to

Pageof 25
Sort By:
The New England Journal of Medicine|December 5, 1985
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancerS A Rosenberg, M T Lotze, L M Muul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1988
Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremityA E Chang, T Kinsella, E Glatstein, et al.
The New England Journal of Medicine|December 22, 1988
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary reportS A Rosenberg, B S Packard, P M Aebersold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot studyS L Topalian, D Solomon, F P Avis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 1992
Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I studyM G Sanda, J C Yang, S L Topalian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1989
Cardiorespiratory effects of immunotherapy with interleukin-2R E Lee, M T Lotze, J M Skibber, et al.
The New England Journal of Medicine|April 9, 1987
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneS A Rosenberg, M T Lotze, L M Muul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapyS N Bock, R E Lee, B Fisher, et al.
Cancer Gene Therapy|April 25, 2015
The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancerB A Boone, L Orlichenko, N E Schapiro, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapyB A Pockaj, J C Yang, M T Lotze, et al.
Pageof 25

Showing results (221-230 of 242) with videos related to

Sort By:
Pageof 25
The New England Journal of Medicine|December 5, 1985
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancerS A Rosenberg, M T Lotze, L M Muul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1988
Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremityA E Chang, T Kinsella, E Glatstein, et al.
The New England Journal of Medicine|December 22, 1988
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary reportS A Rosenberg, B S Packard, P M Aebersold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot studyS L Topalian, D Solomon, F P Avis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 1992
Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I studyM G Sanda, J C Yang, S L Topalian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1989
Cardiorespiratory effects of immunotherapy with interleukin-2R E Lee, M T Lotze, J M Skibber, et al.
The New England Journal of Medicine|April 9, 1987
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneS A Rosenberg, M T Lotze, L M Muul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapyS N Bock, R E Lee, B Fisher, et al.
Cancer Gene Therapy|April 25, 2015
The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancerB A Boone, L Orlichenko, N E Schapiro, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapyB A Pockaj, J C Yang, M T Lotze, et al.
Pageof 25